{"title":"杂交瘤技术:从专利领域的观点","authors":"Phillip R.J. Ansell","doi":"10.1016/S0167-5699(00)01688-1","DOIUrl":null,"url":null,"abstract":"<div><p>The patenting of biological molecules, such as hybridomas and monoclonal antibodies, has become an important issue in biology. While challenging cherished beliefs and practices of many biologists, it has been a central issue for hybridoma and monoclonal antibody research.</p></div>","PeriodicalId":73346,"journal":{"name":"Immunology today","volume":"21 8","pages":"Pages 357-358"},"PeriodicalIF":0.0000,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0167-5699(00)01688-1","citationCount":"4","resultStr":"{\"title\":\"Hybridoma technology: a view from the patent arena\",\"authors\":\"Phillip R.J. Ansell\",\"doi\":\"10.1016/S0167-5699(00)01688-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The patenting of biological molecules, such as hybridomas and monoclonal antibodies, has become an important issue in biology. While challenging cherished beliefs and practices of many biologists, it has been a central issue for hybridoma and monoclonal antibody research.</p></div>\",\"PeriodicalId\":73346,\"journal\":{\"name\":\"Immunology today\",\"volume\":\"21 8\",\"pages\":\"Pages 357-358\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S0167-5699(00)01688-1\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunology today\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0167569900016881\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology today","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0167569900016881","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Hybridoma technology: a view from the patent arena
The patenting of biological molecules, such as hybridomas and monoclonal antibodies, has become an important issue in biology. While challenging cherished beliefs and practices of many biologists, it has been a central issue for hybridoma and monoclonal antibody research.